Promising Nuclear Stocks To Follow Now - March 14th
Oklo, BWX Technologies, Centrus Energy, NuScale Power, Nano Nuclear Energy, Lightbridge, and Karyopharm Therapeutics are the seven Nuclear stocks to watch today, according to MarketBeat's stock...
MarketBeat·1d ago
More News
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company...
MarketBeat·7d ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Significant Increase in Short Interest
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 13th, there was short interest...
MarketBeat·15d ago
Karyopharm Therapeutics Target of Unusually Large Options Trading (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) saw some unusual options trading activity on Thursday. Stock traders acquired 10,965 call options on the company. This represents an...
MarketBeat·17d ago
Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting
Karyopharm Therapeutics (NASDAQ:KPTI) held a virtual special meeting of stockholders on Feb. 18, 2026, to vote on two proposals outlined in the company's proxy materials. The meeting was chaired by...
MarketBeat·20d ago
HC Wainwright Brokers Lift Earnings Estimates for KPTI
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report issued...
MarketBeat·23d ago
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade
The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·25d ago
HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)
HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday...
MarketBeat·25d ago
Promising Nuclear Stocks To Consider - February 16th
Oklo, NuScale Power, Centrus Energy, BWX Technologies, Nano Nuclear Energy, Karyopharm Therapeutics, and Lightbridge are the seven Nuclear stocks to watch today, according to MarketBeat's stock...